dslogo
azlogo

DESTINY-Breast03: Asia Subgroup Patient Characteristics (May 21, 2021 DCO Date)

Patient Disposition

Patient Disposition11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Patient Disposition.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Patient Disposition.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

<p>Patient Disposition.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.</span></span></span></p>

Baseline Characteristics

Baseline Characteristics11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Baseline Characteristics.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

T-DXd

(n=149)

T-DM1

(n=160)

Age, median (range), years54.0 (30.0-77.5)53.4 (20.0-80.6)
Weight, median (range), kg57.0 (39.7-93.0)57.0 (32.1-95.0)
Female, n (%)148 (99.3)160 (100)
Region, n (%)

  • Republic of Korea
37 (24.8)47 (29.4)
  • Japan
37 (24.8) 31 (19.4)
  • China
35 (23.5) 30 (18.8)
  • Taiwan
31 (20.8)40 (25.0)
  • Hong Kong
9 (6.0) 12 (7.5)
HER2 status (IHCa), n (%) 
  • 3+
138 (92.6)142 (88.8)
  • 2+ (ISH amplified)
10 (6.7)17 (10.6)
  • 1+ | not evaluable | not examined
 		0  | 1 (0.7)  |  00  |  1 (0.6)  |  0

ECOG PS, n (%)

  • 0  |  1 


81 (54.4)  |  68 (45.6)  


107 (66.9)  |  53 (33.1)

HR, n (%)

  • Positive  |  negative


68 (45.6)  |  81 (54.4)


74 (46.3)  |  86 (53.8)

History of BM, n (%)

  • Yes  |  no


33 (22.1)  |  116 (77.9)


36 (22.5)  |  124 (77.5)

BM at baseline, n (%)

  • Yes  |  no


24 (16.1)  |  125 (83.9)


30 (18.8)  |  130 (81.3)

History of visceral disease, n (%)

  • Yes  |  no

 

114 (76.5)  |  35 (23.5)

 

116 (72.5)  |  44 (27.5)

aHER2 status as evaluated by central laboratory.

Prior Therapies

Prior Therapies11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Prior Therapies.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.
Characteristic

T-DXd

(n=149)

T-DM1

(n=160)

Prior lines of therapy in the metastatic setting,a n (%)

Median (range)1.0 (1-10)2.0 (0-14)

0

01 (0.6)

1

76 (51.0)75 (46.9)

2

28 (18.8)36 (22.5)

3

14 (9.4)21 (13.1)

4

13 (8.7)14 (8.8)

≥5

18 (12.1)13 (8.1)
Prior cancer therapy,b %

Trastuzumab

100100

Pertuzumab

59.757.5

Other anti-HER2



Anti-HER2 TKI

22.820.6
Other anti-HER2 antibody or ADC00.6
aRapid progressors on (neo)adjuvant therapy were included. Line of therapy does not include endocrine therapy. ; bAll patients received at least 1 prior cancer therapy. One patient with prior T-DM1 treatment was enrolled in error in the T-DXd arm.

Abbreviations

ADC = antibody-drug conjugate

;

BM = brain metastases

;

DCO = data cut-off

;

ECOG = Eastern Cooperative Oncology Group 

;

HER2 = human epidermal growth factor receptor 2

;

HR = hormone receptor

;

IHC = immunohistochemistry

;

ISH = in situ hybridization

;

PS = performance status

;

T-DM1 = trastuzumab emtansine

;

T-DXd = trastuzumab deruxtecan

;

TKI = tyrosine kinase inhibitor

References

1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

©2023 AstraZeneca. All rights reserved.